{"id":1107,"date":"2019-05-14T08:12:37","date_gmt":"2019-05-14T06:12:37","guid":{"rendered":"https:\/\/www.ggkmedia.com\/?p=1107"},"modified":"2020-03-30T21:08:11","modified_gmt":"2020-03-30T19:08:11","slug":"double-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien","status":"publish","type":"post","link":"https:\/\/www.drugsson.com\/sv\/double-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien\/","title":{"rendered":"Double Bond Pharma b\u00f6rjar analysera patientprover fr\u00e5n Inofer-studien"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-repeat:repeat;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:90px;--awb-padding-bottom:90px;--awb-background-color:#eaf7ff;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:30px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h3>Double Bond Pharma b\u00f6rjar analysera patientprover fr\u00e5n Inofer-studien<\/h3>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:50px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;--awb-border-color:#25afb4;--awb-border-bottom:8px;--awb-border-style:solid;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-2\"><p>L\u00e4kemedelsbolaget Double Bond Pharma har nu f\u00e5tt in alla patientprover i den kliniska studien av j\u00e4rntabletterna Inofer. N\u00e4sta steg i studien \u00e4r att f\u00f6retaget, i samarbete med ett l\u00e4mpligt analytiskt laboratorium i Sverige, ska p\u00e5b\u00f6rja analyserna av patientproverna.<\/p>\n<p>\u201dJag \u00e4r mycket glad att arbetet gick s\u00e5 h\u00e4r bra och att vi har f\u00e5tt \u201dLast Patient Out\u201d i andra kvartalet precis som planerat. Vi ser fram emot att f\u00e5 de analyserade resultaten redan till slutet av det h\u00e4r \u00e5ret. Vi f\u00f6rv\u00e4ntar oss att Inofer ger en \u00f6kad j\u00e4rnniv\u00e5 hos hj\u00e4rtsviktspatienter\u201d, kommenterar Igor Lokot, vd f\u00f6r Double Bond Pharma och Drugsson.<\/p>\n<p>Drugsson, som \u00e4r dotterbolaget till Double Bond Pharma, har r\u00e4ttigheterna till Inofer i Sverige, Norge, Danmark och Finland.<\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-text fusion-text-3\"><h4>Nyhetsk\u00e4lla<\/h4>\n<\/div><div class=\"fusion-text fusion-text-4\"><p><a href=\"https:\/\/www.spotlightstockmarket.com\/sv\/market-overview\/nyheter\/nyhets-artikel\/?id=23733&amp;publisher=371\" target=\"_blank\" rel=\"noopener noreferrer\">Spotlight<\/a><\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 boxed-icons has-taglines layout-floated layout-medium-floated layout-small-floated\" style=\"background-color:#f6f6f6;--awb-layout:row;--awb-alignment-small:space-between;\" data-title=\"Double Bond Pharma b\u00f6rjar analysera patientprover fr\u00e5n Inofer-studien\" data-description=\"Double Bond Pharma b\u00f6rjar analysera patientprover fr\u00e5n Inofer-studien    L\u00e4kemedelsbolaget Double Bond Pharma har nu f\u00e5tt in alla patientprover i den kliniska studien av j\u00e4rntabletterna Inofer. N\u00e4sta steg i studien \u00e4r att f\u00f6retaget, i samarbete med ett l\u00e4mpligt analytiskt laboratorium i Sverige, ska p\u00e5b\u00f6rja analyserna av patientproverna.\u201dJag \u00e4r mycket\" data-link=\"https:\/\/www.drugsson.com\/sv\/double-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien\/\"><h4 class=\"tagline\" style=\"color:#4c5166;\">Dela inl\u00e4gget<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1 boxed-icons\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien%2F&amp;t=Double%20Bond%20Pharma%20b%C3%B6rjar%20analysera%20patientprover%20fr%C3%A5n%20Inofer-studien\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#ffffff;background-color:#3b5998;border-color:#3b5998;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Double%20Bond%20Pharma%20b%C3%B6rjar%20analysera%20patientprover%20fr%C3%A5n%20Inofer-studien&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#ffffff;background-color:#000000;border-color:#000000;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-borjar-analysera-patientprover-fran-inofer-studien%2F&amp;title=Double%20Bond%20Pharma%20b%C3%B6rjar%20analysera%20patientprover%20fr%C3%A5n%20Inofer-studien&amp;summary=Double%20Bond%20Pharma%20b%C3%B6rjar%20analysera%20patientprover%20fr%C3%A5n%20Inofer-studien%20%20%20%20%20%20%20%0D%0A%0D%0AL%C3%A4kemedelsbolaget%20Double%20Bond%20Pharma%20har%20nu%20f%C3%A5tt%20in%20alla%20patientprover%20i%20den%20kliniska%20studien%20av%20j%C3%A4rntabletterna%20Inofer.%20N%C3%A4sta%20steg%20i%20studien%20%C3%A4r%20att%20f%C3%B6retaget%2C%20i%20samarbete%20med%20ett%20l%C3%A4mpligt%20analytiskt%20laboratorium%20i%20Sverige%2C%20ska%20p%C3%A5b%C3%B6rja%20analyserna%20av%20patientproverna.%0D%0A%0D%0A%E2%80%9DJag%20%C3%A4r%20mycket\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#ffffff;background-color:#0077b5;border-color:#0077b5;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19,4],"tags":[],"_links":{"self":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1107"}],"collection":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/comments?post=1107"}],"version-history":[{"count":4,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1107\/revisions"}],"predecessor-version":[{"id":1363,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1107\/revisions\/1363"}],"wp:attachment":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/media?parent=1107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/categories?post=1107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/tags?post=1107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}